Latest Articles about UTHR

Earnings Miss at UTHR - Analyst Blog

Zacks Equity Research — Mon, 29 Apr 2013 18:04:08 Z

United Therapeutics Corp. ( UTHR ) reported first-quarter 2013 earnings of $1.19 per share, well below the year-ago earnings of $1.29 and the Zacks Consensus Estimate of $1.47. First

United Therapeutics Corp. (UTHR): Today's Most Compelling Stock Buy

David Moenning — Mon, 22 Apr 2013 22:31:24 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Monday, April 22, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

PSTI Plans to Start Phase I Study - Analyst Blog

Zacks Equity Research — Sat, 20 Apr 2013 00:11:14 Z

Pluristem Therapeutics Inc. ( PSTI ) recently announced its intention to commence a phase I study that will evaluate the safety and efficacy of the local administration of PLacental

UTHR to Move PAH Drug into Phase I - Analyst Blog

Zacks Equity Research — Mon, 15 Apr 2013 20:11:40 Z

United Therapeutics Corporation ( UTHR ) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc. 's ( PSTI ) PLacental eXpanded

Another CRL for UTHR's Oral Remodulin - Analyst Blog

Zacks Equity Research — Wed, 27 Mar 2013 00:26:37 Z

The US Food and Drug Administration (FDA) recently issued a second complete response letter (CRL) for United Therapeutics Corporation's ( UTHR ) new drug application for oral Remodulin

Pipeline Progress at Pluristem - Analyst Blog

Zacks Equity Research — Tue, 26 Mar 2013 02:31:03 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently reported progress on its phase I/II clinical trial, which is evaluating the safety and efficacy of its PLacental eXpanded (PLX)

Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit

Jake L'Ecuyer — Mon, 25 Mar 2013 19:03:29 Z

Following the market opening Monday, the Dow traded up 0.31 percent to 14,556.33 while the NASDAQ gained 0.41 percent to 3,258.20. The S&P also rose, gaining 0.47 percent to 1,564.17.

Pluristem & UTHR Progress with PLX-PAD - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 03:25:01 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently announced that partner United Therapeutics Corporation ( UTHR ) intends to commence a phase I study in Australia using

Another Strong Quarter for UTHR - Analyst Blog

Zacks Equity Research — Thu, 28 Feb 2013 23:44:01 Z

United Therapeutics Corp. ( UTHR ) reported fourth-quarter earnings of $1.60 per share, well above the year-ago earnings of 77 cents and the Zacks Consensus Estimate of $1.25. Higher

Ariad Reports in line 4Q Loss - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 20:10:01 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) reported fourth quarter loss of 36 cents per share, compared with the year-ago loss of 23 cents per share. The Zacks Consensus Estimate for the fourth

Questcor Beats Overall - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 20:00:01 Z

Questcor Pharmaceuticals Inc. ( QCOR ) reported fourth quarter 2012 adjusted earnings per share of $1.09, up 132% from the year-ago period. Earnings surpassed the Zacks Consensus Estimate

Royalty Pharma Eyes Elan Corp. - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 02:40:01 Z

Royalty Pharma, a private entity, recently announced its intention to acquire Elan Corporation, plc ( ELN ). Royalty Pharma intends to acquire Elan at $11 for every share of Elan and its

Generic Segment at Mylan Boosted - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 02:27:43 Z

Mylan Inc. ( MYL ) recently announced that it has launched its generic version of Lupin Atlantis Holdings, S.A.'s Antara capsules (fenofibrate - 43 mg and 130 mg). The company started

Elan Updates Future Plans - Analyst Blog

Zacks Equity Research — Tue, 26 Feb 2013 02:27:37 Z

Elan Corporation, plc ( ELN ) recently provided an update after it announced the restructuring of the Tysabri collaboration with Biogen Idec ( BIIB ). Notably, Biogen gained full

Label Expansion for Astellas - Analyst Blog

Zacks Equity Research — Tue, 26 Feb 2013 02:15:01 Z

Astellas Pharmaceuticals Inc. ( ALPMY ) and Kyowa Hakko Kirin Co., Ltd. recently announced the receipt of Japan's Ministry of Health, Labour and Welfare (MHLW) approval for the drugs,